174 related articles for article (PubMed ID: 27919177)
21. The economic consequences of irritable bowel syndrome: a US employer perspective.
Leong SA; Barghout V; Birnbaum HG; Thibeault CE; Ben-Hamadi R; Frech F; Ofman JJ
Arch Intern Med; 2003 Apr; 163(8):929-35. PubMed ID: 12719202
[TBL] [Abstract][Full Text] [Related]
22. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.
Nellesen D; Yee K; Chawla A; Lewis BE; Carson RT
J Manag Care Pharm; 2013; 19(9):755-64. PubMed ID: 24156644
[TBL] [Abstract][Full Text] [Related]
23. A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain.
Mearin F; Caballero AM; Serra J; Brotons C; Tantiñà A; Fort E; Martínez-Cerezo FJ; Perelló A; Sánchez-Antolín G; Rey E; Angós Musgo R; Berdier R; Gómez-Rodríguez B; Clavé P; García-Alonso M; Torán-Monserrat P; Tack J
Gastroenterol Hepatol; 2019 Mar; 42(3):141-149. PubMed ID: 30612850
[TBL] [Abstract][Full Text] [Related]
24. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
25. Clinical patterns over time in irritable bowel syndrome: symptom instability and severity variability.
Mearin F; Baró E; Roset M; Badía X; Zárate N; Pérez I
Am J Gastroenterol; 2004 Jan; 99(1):113-21. PubMed ID: 14687152
[TBL] [Abstract][Full Text] [Related]
26. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
[TBL] [Abstract][Full Text] [Related]
27. Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome.
Bonafede M; Jing Y; Gdovin Bergeson J; Liffmann D; Makenbaeva D; Graham J; Deitelzweig SB
Hosp Pract (1995); 2011 Aug; 39(3):16-22. PubMed ID: 21881388
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: the Chronic Constipation and IBS-C Treatment and Outcomes Real-World Research Platform (CONTOR).
Taylor DCA; Abel JL; Martin C; Doshi JA; Essoi B; Korrer S; Reasner DS; Carson RT; Hunter AG
J Med Econ; 2020 Oct; 23(10):1072-1083. PubMed ID: 32696684
[TBL] [Abstract][Full Text] [Related]
29. Healthcare spending and utilization for pediatric Irritable Bowel Syndrome in a commercially insured population.
Beinvogl B; Palmer N; Kohane I; Nurko S
Neurogastroenterol Motil; 2021 Nov; 33(11):e14147. PubMed ID: 33818857
[TBL] [Abstract][Full Text] [Related]
30. Variation in Care for Patients with Irritable Bowel Syndrome in the United States.
Lacy BE; Patel H; Guérin A; Dea K; Scopel JL; Alaghband R; Wu EQ; Mody R
PLoS One; 2016; 11(4):e0154258. PubMed ID: 27116612
[TBL] [Abstract][Full Text] [Related]
31. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
32. Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder.
Zhou ZY; Sun S; Chopra P; Zhong Y; Totev T; Signorovitch J
J Med Econ; 2015; 18(11):919-29. PubMed ID: 26121061
[TBL] [Abstract][Full Text] [Related]
33. Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome.
Katsumata R; Shiotani A; Murao T; Ishii M; Fujita M; Matsumoto H; Haruma K
Intern Med; 2017; 56(9):993-999. PubMed ID: 28458330
[TBL] [Abstract][Full Text] [Related]
34. Economic burden of sarcoidosis in a commercially-insured population in the United States.
Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
[TBL] [Abstract][Full Text] [Related]
35. Treatment patterns, symptom reduction, quality of life, and resource use associated with lubiprostone in irritable bowel syndrome constipation subtype.
Solem CT; Patel H; Mehta S; Mody R; Macahilig C; Gao X
Curr Med Res Opin; 2016 May; 32(5):899-905. PubMed ID: 26836030
[TBL] [Abstract][Full Text] [Related]
36. Irritable bowel syndrome--diarrhoea.
Wald A
Best Pract Res Clin Gastroenterol; 2012 Oct; 26(5):573-80. PubMed ID: 23384803
[TBL] [Abstract][Full Text] [Related]
37. The effect of acute serotonergic modulation on rectal motor function in diarrhea-predominant irritable bowel syndrome and healthy controls.
van Nieuwenhoven MA; Kilkens TO
Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1259-65. PubMed ID: 22890209
[TBL] [Abstract][Full Text] [Related]
38. Resource utilization and costs of treating severe rotavirus diarrhea in young Mexican children from the health care provider perspective.
Granados-García V; Velázquez-Castillo R; Garduño-Espinosa J; Torres-López J; Muñoz-Hernández O
Rev Invest Clin; 2009; 61(1):18-25. PubMed ID: 19507471
[TBL] [Abstract][Full Text] [Related]
39. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
Bhowmik D; Hines DM; Intorcia M; Wade RL
J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
[TBL] [Abstract][Full Text] [Related]
40. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.
Olden KW; Chey WD; Shringarpure R; Paul Nicandro J; Chuang E; Earnest DL
Curr Med Res Opin; 2019 Mar; 35(3):461-472. PubMed ID: 30293448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
